Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2016-10-24 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2016年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 Third Quarter Report" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed financial data including balance sheets, income statements, shareholder information, and management assurances about the accuracy of the quarterly report. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (third quarter) indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2016
2016-10-24 Chinese
2016年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 Third Quarter Report" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed financial data for the third quarter of 2016, including main accounting data, financial indicators, shareholder information, important matters, and management's discussion of financial results and outlook. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (the third quarter) clearly identifies this as an Interim / Quarterly Report. The document length is over 11,000 characters, indicating it is the full report, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2016
2016-10-24 Chinese
关于投资参股中科健康（北京）有限公司（筹）的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding its investment in a new company, Zhongke Health (Beijing) Co., Ltd. It details the transaction overview, parties involved, investment proportions, company structure, risk factors, and impact on the company. The document is a formal disclosure of a capital investment transaction and does not contain financial statements or earnings data. It is not a full annual or interim report, nor an earnings release or management discussion. It is not a regulatory certification or a report publication announcement. The content fits best with a Capital/Financing Update as it informs about a new investment and capital participation in a joint venture company. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (5555 characters) and detailed transaction description support this classification with high confidence.
2016-10-24 Chinese
关于收购雅伦生物科技（北京）有限公司股权暨增资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of a majority stake and subsequent capital increase in a biotechnology company by Shenzhen Xinlitai Pharmaceutical Co., Ltd. It includes transaction overview, parties involved, financial data of the target company, board approval, transaction purpose, impact analysis, and risk warnings. The document is a formal announcement of a capital and equity acquisition transaction, with no financial statements or earnings data presented. It is not an earnings release, annual or interim report, or management discussion. The content fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising, financing activities, and capital structure changes related to the acquisition and capital increase. The document length (7766 characters) is sufficient to be the announcement itself, not just a report publication notice. Therefore, the appropriate classification is CAP with high confidence.
2016-10-24 Chinese
关于控股子公司受让美国Salubris Biotherapeutics,Inc.股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a transaction where a controlling subsidiary of Shenzhen Salubris Biotherapeutics Co., Ltd. is acquiring 100% equity of a US company, Salubris Biotherapeutics, Inc., for $1. It details the transaction parties, approval procedures, transaction purpose, and risk factors. The document is relatively short (2654 characters) and focuses on the announcement of the equity acquisition rather than providing financial statements or detailed financial analysis. There is no indication of it being a full financial report, audit report, or regulatory filing. It is a capital/financing update about a share acquisition by a subsidiary, which fits the Capital/Financing Update (CAP) category best.
2016-10-21 Chinese
关于全资子公司增资深圳市科奕顿生物医疗科技有限公司的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the progress of capital increase in its wholly-owned subsidiary, Shenzhen Keyi Dun Biomedical Technology Co., Ltd. It details the acquisition of shares and subsequent capital injections, including specific amounts and changes in ownership percentages. The document is relatively short (1330 characters) and focuses on corporate financing activities related to equity investment and capital increase. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2016-10-20 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.